Humana Inc. (NYSE:HUM) Shares Sold by Wilbanks Smith & Thomas Asset Management LLC

Wilbanks Smith & Thomas Asset Management LLC cut its stake in shares of Humana Inc. (NYSE:HUM) by 15.9% during the 4th quarter, HoldingsChannel.com reports. The fund owned 893 shares of the insurance provider’s stock after selling 169 shares during the period. Wilbanks Smith & Thomas Asset Management LLC’s holdings in Humana were worth $409,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. First Trust Direct Indexing L.P. grew its stake in shares of Humana by 12.2% during the fourth quarter. First Trust Direct Indexing L.P. now owns 3,284 shares of the insurance provider’s stock valued at $1,503,000 after acquiring an additional 358 shares in the last quarter. Essex Financial Services Inc. boosted its holdings in Humana by 20.0% in the fourth quarter. Essex Financial Services Inc. now owns 618 shares of the insurance provider’s stock valued at $283,000 after purchasing an additional 103 shares during the last quarter. Hexagon Capital Partners LLC grew its stake in Humana by 49.4% during the 4th quarter. Hexagon Capital Partners LLC now owns 124 shares of the insurance provider’s stock valued at $56,000 after purchasing an additional 41 shares in the last quarter. Waycross Partners LLC increased its holdings in Humana by 18.5% during the 4th quarter. Waycross Partners LLC now owns 30,546 shares of the insurance provider’s stock worth $13,984,000 after purchasing an additional 4,768 shares during the last quarter. Finally, Savant Capital LLC raised its position in shares of Humana by 25.4% in the 4th quarter. Savant Capital LLC now owns 3,193 shares of the insurance provider’s stock valued at $1,462,000 after purchasing an additional 647 shares in the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Insider Activity at Humana

In related news, Director Jorge S. Mesquita purchased 545 shares of the company’s stock in a transaction on Tuesday, February 20th. The shares were bought at an average cost of $367.09 per share, for a total transaction of $200,064.05. Following the transaction, the director now owns 2,578 shares of the company’s stock, valued at $946,358.02. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.32% of the stock is currently owned by insiders.

Humana Stock Performance

HUM opened at $320.60 on Friday. The company has a current ratio of 1.67, a quick ratio of 1.67 and a debt-to-equity ratio of 0.77. The business’s 50 day moving average is $324.67 and its 200-day moving average is $389.56. The stock has a market cap of $38.63 billion, a PE ratio of 19.96, a price-to-earnings-growth ratio of 1.87 and a beta of 0.49. Humana Inc. has a twelve month low of $298.61 and a twelve month high of $541.21.

Humana (NYSE:HUM) last announced its earnings results on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share for the quarter, beating the consensus estimate of $6.12 by $1.11. Humana had a return on equity of 17.76% and a net margin of 1.82%. The firm had revenue of $29.61 billion for the quarter, compared to the consensus estimate of $28.52 billion. During the same quarter in the previous year, the business earned $9.38 EPS. The firm’s revenue for the quarter was up 10.7% on a year-over-year basis. On average, analysts predict that Humana Inc. will post 16.18 earnings per share for the current year.

Humana Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be given a $0.885 dividend. The ex-dividend date of this dividend is Friday, June 28th. This represents a $3.54 dividend on an annualized basis and a yield of 1.10%. Humana’s dividend payout ratio is presently 22.04%.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. TheStreet cut shares of Humana from a “b” rating to a “c+” rating in a report on Monday, January 8th. StockNews.com lowered Humana from a “strong-buy” rating to a “hold” rating in a report on Friday, January 26th. Wells Fargo & Company lowered their price target on Humana from $413.00 to $350.00 and set an “overweight” rating for the company in a report on Monday, April 8th. Truist Financial reaffirmed a “hold” rating and issued a $550.00 price objective on shares of Humana in a report on Friday, January 19th. Finally, Royal Bank of Canada reduced their price target on shares of Humana from $415.00 to $353.00 and set an “outperform” rating on the stock in a research report on Thursday, April 25th. Eleven research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $424.50.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.